Search research articles
Contact Us
Filters
Showing results (91-100 of 118) with videos related to
Page
of 12
Sort By:
Proceedings of the National Academy of Sciences of the United States of America
|
April 27, 2011
Down-regulation of homeobox genes MEIS1 and HOXA in MLL-rearranged acute leukemia impairs engraftment and reduces proliferation
Kira Orlovsky, Alexander Kalinkovich, Tanya Rozovskaia, et al.
Eclinicalmedicine
|
September 4, 2023
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study
Marek Trněný, Abraham Avigdor, Matthew S McKinney, et al.
Pharmaceutical Research
|
May 3, 2019
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial
Silvia Maria Lavezzi, Jan de Jong, Martine Neyens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2025
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial
Martin Hutchings, Anna Sureda, Francesc Bosch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2007
LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab
Yasodha Natkunam, Pedro Farinha, Eric D Hsi, et al.
Cancer Research
|
October 10, 2025
Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell Lymphoma
Anna Gurevich-Shapiro, Pascale Zwicky, Eitan Winter, et al.
Leukemia & Lymphoma
|
September 28, 2020
Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience
Yafit Segman, Elena Ribakovsky, Abraham Avigdor, et al.
Transplantation and Cellular Therapy
|
November 7, 2022
Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma
Shalev Fried, Roni Shouval, Moneeza Walji, et al.
Leukemia & Lymphoma
|
August 9, 2020
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Graeme A M Fraser, Asher Chanan-Khan, Fatih Demirkan, et al.
British Journal of Haematology
|
July 14, 2026
Real-world outcomes of BrECADD therapy in advanced-stage classical Hodgkin lymphoma: A multicentre retrospective study
Tzvika Porges, Tsofia Levi, Eldad J Dann, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 118) with videos related to
Sort By:
Page
of 12
Proceedings of the National Academy of Sciences of the United States of America
|
April 27, 2011
Down-regulation of homeobox genes MEIS1 and HOXA in MLL-rearranged acute leukemia impairs engraftment and reduces proliferation
Kira Orlovsky, Alexander Kalinkovich, Tanya Rozovskaia, et al.
Eclinicalmedicine
|
September 4, 2023
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study
Marek Trněný, Abraham Avigdor, Matthew S McKinney, et al.
Pharmaceutical Research
|
May 3, 2019
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial
Silvia Maria Lavezzi, Jan de Jong, Martine Neyens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2025
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial
Martin Hutchings, Anna Sureda, Francesc Bosch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2007
LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab
Yasodha Natkunam, Pedro Farinha, Eric D Hsi, et al.
Cancer Research
|
October 10, 2025
Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell Lymphoma
Anna Gurevich-Shapiro, Pascale Zwicky, Eitan Winter, et al.
Leukemia & Lymphoma
|
September 28, 2020
Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience
Yafit Segman, Elena Ribakovsky, Abraham Avigdor, et al.
Transplantation and Cellular Therapy
|
November 7, 2022
Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma
Shalev Fried, Roni Shouval, Moneeza Walji, et al.
Leukemia & Lymphoma
|
August 9, 2020
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Graeme A M Fraser, Asher Chanan-Khan, Fatih Demirkan, et al.
British Journal of Haematology
|
July 14, 2026
Real-world outcomes of BrECADD therapy in advanced-stage classical Hodgkin lymphoma: A multicentre retrospective study
Tzvika Porges, Tsofia Levi, Eldad J Dann, et al.
Page
of 12